M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
Novartis reports study results of Afinitor and Sandostatin LAR in patients pancreatic neuroendocrine tumours
24 June 2009 - Swiss Novartis AG (VTX: NOVN) reported today (24 June) results from a Phase II study of Afinitor (everolimus) Tablets in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy in patients with pancreatic neuroendocrine tumours (NET)....
If you want to view the full text of this story, you must first purchase archive retrieval credits.